Can Eptifibatide Rewrite the NSTEMI Story? (Eptifibatide vs. Standard Care for NSTEMI: A 5-Year Analysis of Major Adverse Cardiovascular Events).

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions Pub Date : 2025-10-21 DOI:10.1002/ccd.70242

Parvin Kalhor, Pargol Nowrouzi, Parichehr Ghahari, Mehdi Mehrani

{"title":"Can Eptifibatide Rewrite the NSTEMI Story? (Eptifibatide vs. Standard Care for NSTEMI: A 5-Year Analysis of Major Adverse Cardiovascular Events).","authors":"Parvin Kalhor, Pargol Nowrouzi, Parichehr Ghahari, Mehdi Mehrani","doi":"10.1002/ccd.70242","DOIUrl":null,"url":null,"abstract":"Background: Coronary artery disease (CAD) is a leading cause of death worldwide. Among acute coronary syndromes, non-ST-elevation myocardial infarction (NSTEMI) poses a higher long-term risk than ST-elevation myocardial infarction (STEMI). Eptifibatide, a glycoprotein IIb/IIIa inhibitor, is used during percutaneous coronary intervention (PCI) to prevent clots, but its long-term effects in NSTEMI patients remain unclear.Aims: This study assesses the impact of Eptifibatide on major adverse cardiac events (MACE) and survival in NSTEMI patients undergoing PCI.Methods: A retrospective cohort study of NSTEMI patients treated between 2015 and 2022 at Tehran Heart Center. Patients were grouped based on whether they received Eptifibatide. MACE outcomes were tracked during hospitalization and 1 year later. Statistical adjustments were made for baseline differences.Results: Among 5309 patients, 12% received Eptifibatide. There were no significant differences between groups in MACE (17.2% vs. 15.6%) or survival (HR 0.97, p = 0.901).Conclusion: Eptifibatide showed no significant effect on MACE or survival in NSTEMI patients undergoing PCI. Further research is needed to explore its role in high-risk subgroups.","PeriodicalId":520583,"journal":{"name":"Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/ccd.70242","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Coronary artery disease (CAD) is a leading cause of death worldwide. Among acute coronary syndromes, non-ST-elevation myocardial infarction (NSTEMI) poses a higher long-term risk than ST-elevation myocardial infarction (STEMI). Eptifibatide, a glycoprotein IIb/IIIa inhibitor, is used during percutaneous coronary intervention (PCI) to prevent clots, but its long-term effects in NSTEMI patients remain unclear.

Aims: This study assesses the impact of Eptifibatide on major adverse cardiac events (MACE) and survival in NSTEMI patients undergoing PCI.

Methods: A retrospective cohort study of NSTEMI patients treated between 2015 and 2022 at Tehran Heart Center. Patients were grouped based on whether they received Eptifibatide. MACE outcomes were tracked during hospitalization and 1 year later. Statistical adjustments were made for baseline differences.

Results: Among 5309 patients, 12% received Eptifibatide. There were no significant differences between groups in MACE (17.2% vs. 15.6%) or survival (HR 0.97, p = 0.901).

Conclusion: Eptifibatide showed no significant effect on MACE or survival in NSTEMI patients undergoing PCI. Further research is needed to explore its role in high-risk subgroups.

查看原文本刊更多论文

依替菲肽能改写NSTEMI的故事吗？依替巴肽与标准治疗NSTEMI：主要不良心血管事件的5年分析)。

背景：冠状动脉疾病（CAD）是世界范围内死亡的主要原因。在急性冠状动脉综合征中，非st段抬高型心肌梗死（NSTEMI）的长期风险高于st段抬高型心肌梗死（STEMI）。Eptifibatide是一种糖蛋白IIb/IIIa抑制剂，用于经皮冠状动脉介入治疗（PCI）以预防血栓，但其对NSTEMI患者的长期影响尚不清楚。目的：本研究评估eptifitide对接受PCI的NSTEMI患者的主要不良心脏事件（MACE）和生存率的影响。方法：对2015年至2022年在德黑兰心脏中心治疗的非stemi患者进行回顾性队列研究。患者根据是否接受依替巴肽进行分组。在住院期间和1年后追踪MACE结果。对基线差异进行统计调整。结果：5309例患者中，12%的患者接受了依替巴肽治疗。两组间MACE （17.2% vs 15.6%）和生存率（HR 0.97, p = 0.901）差异无统计学意义。结论：依替巴肽对接受PCI治疗的非stemi患者的MACE和生存率无显著影响。需要进一步的研究来探索其在高危亚群中的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions

自引率

0.00%

发文量